Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal lysine aspirin provocation versus history taking for diagnosis of AERD in CRSwNP
2022-000215-31Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lysine acetylsalicylate and sodium chloride in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD) and chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by UZ Leuven. Primary endpoint: Diagnostic performance. Started Apr 2022; status: completed.
02
Drugs
lysine acetylsalicylatesodium chloride
03
Conditions
nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2022-000215-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000215-31.